84163-13-3Relevant articles and documents
Purification method of 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride
-
, (2021/04/10)
The invention discloses a purification method of a risperidone intermediate 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride as shown in a formula II, which is characterized by comprising the following steps: adding 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride into ethanol, adding a certain amount of water, and carrying out heating reflux until the solution is clear to obtain the risperidone intermediate 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride; and cooling the compound to a certain temperature for crystal growing, then cooling the mixture to -5 to 10 DEG C, and filtering and drying the mixture to obtain the crystal. According to the purification method of the 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride, the dimer shown as the formula V can be effectively separated out, the purification yield is 85% or above, the chemical purity of a finished product can reach 99.9% or above, an amplification effect cannot be generated in large-scale production, and the process is stable.
Preparation method of risperidone
-
Paragraph 0030-0037, (2019/04/02)
The invention discloses a preparation method of risperidone, and belongs to the technical field of preparation methods for chemical medical intermediates. High-purity risperidone is prepared by performing oximation, cyclization and condensation reactions on 2,4- difluorophenyl-4,-piperidone methanone hydrochloride and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyridino-[1,2-a]pyridine-4-ketone as raw materials. The method disclosed by the invention has the advantages of adoption of relatively cheap and readily-available raw materials, easiness in operation, higher yield and higher industrial value.
PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF
-
Page/Page column 36, (2008/12/08)
The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.